keytruda - Search News

Merck, Keytruda and Neck Cancers

Hosted on MSN · 14h

Merck expects cancer therapy Keytruda to be part of government price setting in 2026

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028. The company said in a regulatory filing it expects U.

Seeking Alpha on MSN · 13h

Merck expects Keytruda to face HHS price setting in 2026

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with the SEC,

MarketWatch · 1d

Merck Gets Speedy FDA Review of Keytruda in Certain Head, Neck Cancers

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

The Pharma Letter · 21h

FDA grants priority review to Merck’s sBLA for Keytruda

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for Keytruda (pembrolizumab) for a new indication.

3hon MSN

A little-known Chinese company made a drug that beat the world’s biggest selling medicine

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

FDA Accepts Priority Review for Pre- and Postsurgical Keytruda in HNSCC

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

1d

Merck’s application for keytruda in HNSCC granted priority review by FDA

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

Microbiotica unveils new data on MB097 at AACR IO meeting

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

1d

Pfizer: What The Summit Therapeutics Deal Brings

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

1d

Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11

Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...

Healthcare Headlines: From West Bank Violence to Overdose Decline

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...

GlobalData on MSN1d

Pfizer sets sights on Summit’s bispecific in combo with its ADCs

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results